Results 171 to 180 of about 16,301 (208)
Innovative methods in evaluating the effects of lipid-lowering medication on bone tissue. [PDF]
Sci RepMoldovan I +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Acta Crystallographica Section C Crystal Structure Communications, 2005
Unlike the related fenofibrate molecule [Henry, Zhang, Gao & Bruckner (2003). Acta Cryst. E59, o699-o700], fenofibric acid {systematic name: 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid}, C17H15ClO4, contains a carboxylic acid moiety instead of an ester moiety. This polar moiety plays an important role in the formation of a rare acid-to-ketone
Nigam P, Rath +2 more
openaire +2 more sources
Unlike the related fenofibrate molecule [Henry, Zhang, Gao & Bruckner (2003). Acta Cryst. E59, o699-o700], fenofibric acid {systematic name: 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid}, C17H15ClO4, contains a carboxylic acid moiety instead of an ester moiety. This polar moiety plays an important role in the formation of a rare acid-to-ketone
Nigam P, Rath +2 more
openaire +2 more sources
Atherosclerosis, 1994
Rationale and development of a new fenofibrate formulation is described. A lower dispersion of particles size and thereby a better absorption rate leads to a decrease of the daily dose and provides a better control of the amount absorbed. Improved reproducibility of the pharmacological and therapeutic effect is expected.
A, Munoz, J P, Guichard, P, Reginault
openaire +2 more sources
Rationale and development of a new fenofibrate formulation is described. A lower dispersion of particles size and thereby a better absorption rate leads to a decrease of the daily dose and provides a better control of the amount absorbed. Improved reproducibility of the pharmacological and therapeutic effect is expected.
A, Munoz, J P, Guichard, P, Reginault
openaire +2 more sources
Cardiovascular Drug Reviews, 2002
ABSTRACTFenofibrate is a fibric acid derivative that has been marketed since the mid‐1970's (1998 in the United States). Its active metabolite, fenofibric acid, is responsible for the primary pharmacodynamic effects of the drug: reductions in total plasma cholesterol, lowdensity lipoprotein cholesterol, triglycerides, and very low‐density lipoprotein ...
openaire +2 more sources
ABSTRACTFenofibrate is a fibric acid derivative that has been marketed since the mid‐1970's (1998 in the United States). Its active metabolite, fenofibric acid, is responsible for the primary pharmacodynamic effects of the drug: reductions in total plasma cholesterol, lowdensity lipoprotein cholesterol, triglycerides, and very low‐density lipoprotein ...
openaire +2 more sources
The American Journal of Medicine, 1987
This discussion outlines the major aspects of the human pharmacology of fenofibrate, a hypolipidemic agent. In view of its short half-life, efficient absorption, and elimination, fenofibrate would not appear to accumulate in either plasma or tissues. It is extensively absorbed only in the presence of food and is transported through the bloodstream by ...
openaire +2 more sources
This discussion outlines the major aspects of the human pharmacology of fenofibrate, a hypolipidemic agent. In view of its short half-life, efficient absorption, and elimination, fenofibrate would not appear to accumulate in either plasma or tissues. It is extensively absorbed only in the presence of food and is transported through the bloodstream by ...
openaire +2 more sources
Fenofibrate and fenofibric acid analysis by capillary electrophoresis
ELECTROPHORESIS, 2004AbstractA capillary electrophoresis method has been developed to measure fenofibrate in capsules based on micellar electrokinetic capillary chromatography with detection at 280 nm using a borate buffer containing sodium dodecyl sulfate (SDS). However, the metabolite of this drug (fenofibric acid) in serum and whole blood was analyzed by capillary zone ...
openaire +2 more sources